| Biomarker ID | 1434 |
| PMID | 24893170 |
| Year | 2014 |
| Biomarker | miR-19b |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Cases |
| Odds Ratio/Hazard Ratio/Relative Risk | OR: 12.67 (95% CI: 2.72-58.98) p=0.001 |
| Effect on Pathways | Pathways include: DNA-binding transcription factor activity, RNA polymerase II-specific; DNA-binding transcription factor activity; nuclear chromatin; nuclear chromosome; chromatin, |
| Experiment | Gleason Score ≥7 or Gleason Score =6 |
| Type of Biomarker | Prognostic |
| Cohort | A validation cohort consisted of 25 cases and 35 controls. Gleason score of 7 or higher (case group) and a pathologic Gleason score of 6 (control group). |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.86 (95% CI: 0.76-0.96) |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |